Zhou Fang, Huang Qiong, Dai Xingping, Yin Jiye, Wu Jing, Zhou Honghao, Gong Zhicheng, Liu Zhaoqian
Central South University, Changsha, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Oct;36(10):949-57. doi: 10.3969/j.issn.1672-7347.2011.10.004.
To explore the association between rs3758539G-803A and rs10882283T-179G polymorphism of retinol binding protein 4 (RBP4) and rosiglitazone response in Chinese type 2 diabetes mellitus (T2DM) patients.
A total of 472 Chinese T2DM patients and 198 healthy subjects were enrolled to identify G-803A and T-179G genotypes using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. Forty-two T2DM patients with different G-803A or T-179G genotypes were selected to undergo a 12-week rosiglitazone treatment (4 mg/d). Serum fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting serum insulin (FINS), glycated hemoglobin (HbAlc), postprandial serum insulin (PINS), triglyceride (TG), low-density lipoprotein-cholesterol (LDL-c), and high-density lipoprotein-cholesterol (HDL-c) were determined before and after the rosiglitazone treatment.
T2DM patients with RBP4 G-803A GG genotype showed lower TG and LDL-c concentrations compared with that in the GA+AA genotype subjects. T2DM patients with RBP4 T-179G TT genotype showed lower waist-to-hip ratio (WHR), FPG and FINS values compared with that in the TG+GG genotype individuals. Patients with GG genotype of RBP4 G-803A had an enhanced rosiglitazone efficacy on FPG and FINS compared with that in the GA+AA genotype group. Patients with RBP4 T-179G TG+GG genotype showed an enhanced rosiglitazone efficacy on HbAlc level compared with that in the TT genotype group.
RBP4 G-803A and T-179G polymorphism might be associated with the development of T2DM and affect the therapeutic efficacy of rosignitazone in Chinese T2DM patients.
探讨视黄醇结合蛋白4（RBP4）基因rs3758539G-803A和rs10882283T-179G多态性与中国2型糖尿病（T2DM）患者罗格列酮疗效之间的关联。
共纳入472例中国T2DM患者和198例健康受试者，采用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）分析法鉴定G-803A和T-179G基因型。选择42例具有不同G-803A或T-179G基因型的T2DM患者接受为期12周的罗格列酮治疗（4mg/d）。在罗格列酮治疗前后测定血清空腹血糖（FPG）、餐后血糖（PPG）、空腹血清胰岛素（FINS）、糖化血红蛋白（HbAlc）、餐后血清胰岛素（PINS）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-c）和高密度脂蛋白胆固醇（HDL-c）。
与GA+AA基因型受试者相比，RBP4 G-803A GG基因型的T2DM患者TG和LDL-c浓度较低。与TG+GG基因型个体相比，RBP4 T-179G TT基因型的T2DM患者腰臀比（WHR）、FPG和FINS值较低。与GA+AA基因型组相比，RBP4 G-803A GG基因型患者罗格列酮对FPG和FINS的疗效增强。与TT基因型组相比，RBP4 T-179G TG+GG基因型患者罗格列酮对HbAlc水平的疗效增强。
RBP4 G-803A和T-179G多态性可能与T2DM的发生有关，并影响罗格列酮在中国T2DM患者中的治疗效果。
